AGA
VRTX icon

Accuvest Global Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Accuvest Global Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-845
Closed -$297K – 132
2023
Q2 		$297K Sell
845
-58
-6% -$19.5K 0.15% 98
2023
Q1 		$285K Sell
903
-903
-50% -$271K 0.13% 112
2022
Q4 		$522K Buy
+1,806
New +$550K 0.17% 88

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Accuvest Global Advisors's VRTX Position: Q3 2023 in Review

Accuvest Global Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 845 shares — an estimated $297K sold.

Accuvest Global Advisors first reported a position in VRTX in Q4 2022 and held it in 3 quarters. The position peaked at $522K in Q4 2022. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

  • Accuvest Global Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Accuvest Global Advisors sold 845 Vertex Pharmaceuticals shares in Q3 2023, an estimated $297K.
  • Accuvest Global Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Accuvest Global Advisors's Vertex Pharmaceuticals position peaked at $522K in Q4 2022.
  • 1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Accuvest Global Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.